Related Experiment Video

Updated: Jun 17, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Comparative assessment of angiotensin receptor blockers in different clinical settings

Paolo Verdecchia1, Fabio Angeli, Salvatore Repaci

  • 1Struttura Complessa di Cardiologia, Unità di Ricerca Clinica 'Cardiologia Preventiva', Ospedale S. Maria della Misericordia, Perugia, Italy. verdec@tin.it

Vascular Health and Risk Management
|December 10, 2009
PubMed

Insights

Angiotensin receptor blockers (ARBs) effectively manage cardiovascular and renal disease progression. However, specific ARB properties influence clinical efficacy, making direct generalization of study results misleading.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Cardiovascular and renal diseases share a continuum from risk factors to clinical syndromes.
  • Blood pressure control is crucial for cardiovascular disease prevention.
  • The renin-angiotensin system significantly impacts cardiovascular disease progression.

Purpose of the Study:

  • To provide a comparative assessment of different angiotensin receptor blockers (ARBs).
  • To evaluate the efficacy of ARBs on major clinical endpoints across the cardiovascular disease continuum.
  • To highlight the importance of specific ARB pharmacological properties on clinical outcomes.

Main Methods:

  • Review of clinical studies and evidence on angiotensin receptor blockers.
  • Comparative analysis of ARB efficacy on cardiovascular and renal disease progression.
  • Assessment of clinical benefits and differences among various ARBs.

Main Results:

  • Angiotensin receptor blockers (ARBs) demonstrate effectiveness in slowing cardiovascular disease progression.
  • Significant pharmacological differences exist among ARBs, impacting their clinical efficacy.
  • Generalizing results from one ARB to all ARBs may be misleading due to these differences.

Conclusions:

  • Understanding specific ARB properties is essential for optimizing treatment strategies.
  • Tailoring ARB selection based on individual patient profiles and drug characteristics is recommended.
  • Further comparative studies are needed to elucidate the nuanced efficacy of different ARBs.

Keywords:
eprosartanhypertensionirbesartanlosartanolmesartanrenin–angiotensin systemtelmisartanvalsartan

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...